- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04590196
Effect of Oral Curcumin Supplementation in Dry Age-related Macular Degeneration (AMD) Patients
June 20, 2023 updated by: Yekaterina Joltikov, University of Illinois at Chicago
Effect of Oral Curcumin Supplementation on Choriocapillaris and Drusen Characteristics Measured by Multimodal Retinal Imaging in Dry Age-related Macular Degeneration (AMD) Patients
Nutrition plays an important role in preventing progression of dry age related macular degeneration (AMD), a disease of aging that leads to drusen deposits in the macula causing significant decrease in vision.
Drusen contains amyloid protein which is inhibited by curcumin, a natural plant based antioxidant.
Oral Longvida curcumin has been shown to accumulate in the retina of human subjects within 10 days of supplementation.
This study aims to investigate the duration of oral curcumin supplementation needed to see clinical impact in reducing volume and number of drusen and decreasing choriocapillaris density loss or flow impairment in dry AMD patients.
Patients will be given a 12-month course of oral Longvida curcumin and clinical impact will be measured by multimodal retinal imaging (fundus photos, OCT and OCT-A) at day 0, month 3, month 6, and month 12 of supplementation.
Previous small studies have shown change in drusen size within 4 6months of curcumin supplementation, given that drusen can naturally fluctuate in size, we want to have a longer study period with a control group to better understand the effects of curcumin on drusen characteristics.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Rajvi Mehta, MD
- Phone Number: 312-970-1806
- Email: mehta@uic.edu
Study Contact Backup
- Name: Jennifer Lim, MD
- Phone Number: 312-996-6562
- Email: jennylim@uic.edu
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Illinois Eye and Ear Infirmary
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
48 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Age > 50 years old BCVA 20/20 to 20/400 Dry AMD with many large (>300 μm in diameter and more than 100 μm in height) soft drusenoid PEDs
Exclusion Criteria:
- presence (or history) of significant geographic atrophy or choroidal neovascularization in either eye; history of eye surgery (other than cataract extraction) within 90 days, history of BRVO/CRVO, Macular hole, pathologic myopia, uveitis, pseudovitelliform maculopathy will be excluded.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: treatment
|
longvida curcumin verdure sciences formulation
|
Placebo Comparator: control
|
Composition of Placebo : 95.66% Maltodextrin 0.34% Sunset Yellow Color 0.06% Tartrazine Food Color 3.91% Silicon Dioxide |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Drusen volume
Time Frame: baseline, 3month, 6month, 12 month timepoints
|
Quantify change in volume of drusen/drusenoid pigment epithelial detachments at day 0, month 3, month 6, month 12 by comparing fundus photos and OCT images obtained at these time points
|
baseline, 3month, 6month, 12 month timepoints
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Drusen size
Time Frame: baseline, 3month, 6month, 12 month timepoints
|
Quantify change in size of drusen/drusenoid pigment epithelial detachments at day 0, month 3, month 6, month 12 by comparing diameter of drusen in OCT images obtained at these time points
|
baseline, 3month, 6month, 12 month timepoints
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Yekaterina Joltikov, MD, University of Illinois at Chicago
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2020
Primary Completion (Actual)
June 1, 2023
Study Completion (Actual)
June 1, 2023
Study Registration Dates
First Submitted
October 4, 2020
First Submitted That Met QC Criteria
October 11, 2020
First Posted (Actual)
October 19, 2020
Study Record Updates
Last Update Posted (Actual)
June 22, 2023
Last Update Submitted That Met QC Criteria
June 20, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Macular Degeneration
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Curcumin
Other Study ID Numbers
- 2019-0566
- 096625 (Other Grant/Funding Number: Illinois Society for the Prevention of Blindness)
- 098928 (Other Grant/Funding Number: VitreoRetinal Surgery Foundation)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Age Related Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheRecruitingNeovascular Age-Related Macular DegenerationBelgium, United States, United Kingdom, Italy, Argentina, Spain, Israel, Australia, Austria, Brazil, Germany, Switzerland, Taiwan, France
-
Hoffmann-La RocheCompletedNeovascular Age-Related Macular DegenerationUnited States
-
First Affiliated Hospital of Chongqing Medical...Enrolling by invitationExudative Age-Related Macular DegenerationChina
-
Novartis PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
Clinical Trials on Longvida curcumin
-
University of California, Los AngelesCompleted
-
Jaslok Hospital and Research CentreUniversity of California, Los Angeles; Verdure Sciences; Pharmanza Herbal Pvt...Terminated
-
Tata Memorial CentreRecruitingOral Mucositis (Ulcerative)India
-
Tata Memorial CentreCompletedOral Mucositis (Ulcerative)India
-
VA Office of Research and DevelopmentUnknownMild Cognitive ImpairmentUnited States
-
University of Colorado, DenverCompletedPolycystic Kidney, Autosomal DominantUnited States
-
University of IowaWithdrawnChronic Kidney Diseases | Blood Pressure | Hyperemia | Vasoconstriction
-
University of Illinois at ChicagoVerdure SciencesActive, not recruiting
-
Diana JalalUniversity of Colorado, Denver; Stanford University; University of Colorado,...CompletedChronic Kidney Diseases | Cognitive DeclineUnited States
-
H.K.E.S's S.Nijalingappa Institute of Dental Science...Unknown